Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
EMERYVILLE, Calif., March 28, 2017 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is scheduled to present at the Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 10:40 a.m. Eastern Time.
The presentation will be webcast live from the Investor section of the Adamas website at http://ir.adamaspharma.com/events.cfm and available through May 4, 2017.
About Adamas Pharmaceuticals, Inc.
Adamas develops new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Parkinson’s disease, multiple sclerosis, epilepsy and Alzheimer’s disease. Adamas has pioneered a platform to develop medicines, called chrono-synchronous therapies, for chronic neurologic disorders based on an understanding of the time-dependent biologic processes responsible for disease activity and drug response to potentially achieve symptomatic relief without tolerability issues. The company’s most advanced product candidate, ADS-5102, is in development for levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease and walking impairment. An NDA supporting ADS-5102 for the treatment of LID in patients with Parkinson’s disease is under review by the FDA, with a PDUFA date of August 24, 2017. Adamas is exploring other indications for ADS-5102 for further development. Adamas is also investigating ADS-4101 for the treatment of partial onset seizures in patients with epilepsy. Additionally, Adamas’ licensed assets, NAMENDA XR® and NAMZARIC®, are currently marketed by Allergan, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH & Co. KGaA.
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3567 [email protected]
